Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives
2024

Insights on Ameloblastomas Treated with Targeted Therapies

Sample size: 14 publication 10 minutes Evidence: moderate

Author Information

Author(s): Hirschhorn Ariel, Grynberg Shirly, Campino Gadi Abebe, Dobriyan Alex, Patel Vinod, Greenberg Gahl, Yacobi Rinat, Barshack Iris, Yahalom Ran, Toren Amos, Vered Marilena

Primary Institution: Chaim Sheba Medical Center, Tel Hashomer, Israel

Hypothesis

The study aimed to characterize the effect of post-treatment histomorphologic changes in BRAF-mutated ameloblastomas treated with targeted therapies.

Conclusion

The study provides preliminary evidence that ameloblastomas can undergo significant histomorphologic changes in response to targeted treatment, suggesting a potential for complete response.

Supporting Evidence

  • Patients with BRAF-mutated ameloblastomas showed significant histomorphologic changes post-treatment.
  • Near-complete and partial responses were observed in the treated tumors.
  • Inflammatory responses were noted as a significant finding in post-treated tumors.
  • Squamous differentiation was a common feature in post-treatment ameloblastomas.
  • Duration of treatment correlated positively with stromal scores.
  • Immunostaining revealed variable expression of p16 in neoplastic epithelium and stroma.
  • Granulomatous inflammation was associated with treatment duration.
  • Post-treatment evaluation is essential for assessing tumor response and planning further treatment.

Takeaway

This study shows that a special type of jaw tumor called ameloblastoma can shrink a lot when treated with specific medicines, which helps doctors save the jaw and avoid big surgeries.

Methodology

The study included 14 patients with BRAF-mutated ameloblastomas, assessing histomorphologic changes post-treatment using a scoring system for epithelial and stromal components.

Limitations

The small sample size and lack of pre-treatment specimens for some patients limited the comparison of morphological and molecular features.

Participant Demographics

Patients included 11 with mandibular tumors and 3 with maxillary tumors, aged between 10 and 83 years.

Statistical Information

P-Value

p=0.55

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s12105-024-01734-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication